Clinical Trials Logo

Recurrent Salivary Gland Cancer clinical trials

View clinical trials related to Recurrent Salivary Gland Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05010629 Active, not recruiting - Metastatic Cancer Clinical Trials

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names of the study drug(s) involved in this study are: - 9-ING-41 (a GSK-3β inhibitor) - Carboplatin chemotherapy

NCT ID: NCT01847326 Active, not recruiting - Tongue Cancer Clinical Trials

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

Start date: March 26, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with carboplatin followed by chemoradiation in treating patients with recurrent head and neck cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, carboplatin, fluorouracil, and hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel albumin-stabilized nanoparticle formulation followed by chemoradiation therapy may be an effective treatment for head and neck cancer.